The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.
10.1016/j.apsb.2022.06.003
- Author:
Juan PANG
1
;
Jia Nuo FENG
2
;
Wenhua LING
1
;
Tianru JIN
2
Author Information
1. Department of Nutrition, School of Public Health, Sun Yat-sen Universitynstitute, Guangzhou 510080, China.
2. Division of Advanced Diagnostics, Toronto General Hospital Research I, University Health Network, Toronto M5G 1L7, Canada.
- Publication Type:Review
- Keywords:
Anti-inflammation;
Exenatide;
GLP-1R;
GLP-1RAs;
Liraglutide;
Lung injury;
MSC-based therapy;
TxNIP
- From:
Acta Pharmaceutica Sinica B
2022;12(11):4040-4055
- CountryChina
- Language:English
-
Abstract:
Since 2005, GLP-1 receptor (GLP-1R) agonists (GLP-1RAs) have been developed as therapeutic agents for type 2 diabetes (T2D). GLP-1R is not only expressed in pancreatic islets but also other organs, especially the lung. However, controversy on extra-pancreatic GLP-1R expression still needs to be further resolved, utilizing different tools including the use of more reliable GLP-1R antibodies in immune-staining and co-immune-staining. Extra-pancreatic expression of GLP-1R has triggered extensive investigations on extra-pancreatic functions of GLP-1RAs, aiming to repurpose them into therapeutic agents for other disorders. Extensive studies have demonstrated promising anti-inflammatory features of GLP-1RAs. Whether those features are directly mediated by GLP-1R expressed in immune cells also remains controversial. Following a brief review on GLP-1 as an incretin hormone and the development of GLP-1RAs as therapeutic agents for T2D, we have summarized our current understanding of the anti-inflammatory features of GLP-1RAs and commented on the controversy on extra-pancreatic GLP-1R expression. The main part of this review is a literature discussion on GLP-1RA utilization in animal models with chronic airway diseases and acute lung injuries, including studies on the combined use of mesenchymal stem cell (MSC) based therapy. This is followed by a brief summary.
